Novavax Inc (NVAX) stock
NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.96−0.10 (-1.24%)
Close on Nov 17, 2026Market cap $1.31BP/E –Yield –
Novavax r&d expenses
Research and development expenses are spending on new products and technology.
Novavax's R&D Expenses for the twelve months ending Jun 30, 2026 was $340.32M, down 5.4% year over year. For fiscal 2025 it was $342.32M, down 12.5% from the year before. Over ten years it grew 7.7% a year on average. The highest annual figure on record is $2.53B in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $342.32M | -12.5% |
| FY2024 | Dec 31, 2024 | $391.17M | -47.0% |
| FY2023 | Dec 31, 2023 | $737.50M | -40.3% |
| FY2022 | Dec 31, 2022 | $1.24B | -51.3% |
| FY2021 | Dec 31, 2021 | $2.53B | +239.3% |
| FY2020 | Dec 31, 2020 | $747.03M | +556.2% |
| FY2019 | Dec 31, 2019 | $113.84M | -34.5% |
| FY2018 | Dec 31, 2018 | $173.80M | +3.2% |
| FY2017 | Dec 31, 2017 | $168.44M | -29.2% |
| FY2016 | Dec 31, 2016 | $237.94M | +46.3% |
| FY2015 | Dec 31, 2015 | $162.64M | +72.3% |
| FY2014 | Dec 31, 2014 | $94.42M | +61.3% |
| FY2013 | Dec 31, 2013 | $58.53M | +117.5% |
| FY2012 | Dec 31, 2012 | $26.91M | +46.5% |
| FY2011 | Dec 31, 2011 | $18.36M | -34.5% |
| FY2010 | Dec 31, 2010 | $28.03M | +8.7% |
| FY2009 | Dec 31, 2009 | $25.78M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $70.69M | -10.8% |
| Q1 FY2026 | Mar 31, 2026 | $95.47M | +7.3% |
| Q4 FY2025 | Dec 31, 2025 | $75.88M | -27.3% |
| Q3 FY2025 | Sep 30, 2025 | $98.27M | +12.7% |
| Q2 FY2025 | Jun 30, 2025 | $79.23M | -25.9% |
| Q1 FY2025 | Mar 31, 2025 | $88.94M | -4.0% |
| Q4 FY2024 | Dec 31, 2024 | $104.38M | -36.6% |
| Q3 FY2024 | Sep 30, 2024 | $87.16M | -17.9% |
| Q2 FY2024 | Jun 30, 2024 | $106.95M | -51.3% |
| Q1 FY2024 | Mar 31, 2024 | $92.68M | -62.5% |
| Q4 FY2023 | Dec 31, 2023 | $164.70M | -36.1% |
| Q3 FY2023 | Sep 30, 2023 | $106.23M | -65.1% |
| Q2 FY2023 | Jun 30, 2023 | $219.48M | -24.2% |
| Q1 FY2023 | Mar 31, 2023 | $247.10M | -35.6% |
| Q4 FY2022 | Dec 31, 2022 | $257.85M | -73.2% |
| Q3 FY2022 | Sep 30, 2022 | $304.30M | -25.5% |
| Q2 FY2022 | Jun 30, 2022 | $289.65M | -49.2% |
| Q1 FY2022 | Mar 31, 2022 | $383.48M | -35.3% |
| Q4 FY2021 | Dec 31, 2021 | $962.96M | +140.0% |
| Q3 FY2021 | Sep 30, 2021 | $408.20M | +38.8% |
| Q2 FY2021 | Jun 30, 2021 | $570.69M | +1537.7% |
| Q1 FY2021 | Mar 31, 2021 | $592.67M | +3408.0% |
| Q4 FY2020 | Dec 31, 2020 | $401.20M | +1267.4% |
| Q3 FY2020 | Sep 30, 2020 | $294.09M | +1480.2% |
| Q2 FY2020 | Jun 30, 2020 | $34.85M | +14.6% |
| Q1 FY2020 | Mar 31, 2020 | $16.90M | -52.4% |
| Q4 FY2019 | Dec 31, 2019 | $29.34M | -32.4% |
| Q3 FY2019 | Sep 30, 2019 | $18.61M | -55.0% |
| Q2 FY2019 | Jun 30, 2019 | $30.42M | -31.7% |
| Q1 FY2019 | Mar 31, 2019 | $35.47M | -20.3% |
| Q4 FY2018 | Dec 31, 2018 | $43.42M | -12.6% |
| Q3 FY2018 | Sep 30, 2018 | $41.33M | -1.3% |
| Q2 FY2018 | Jun 30, 2018 | $44.54M | +13.4% |
| Q1 FY2018 | Mar 31, 2018 | $44.51M | +18.2% |
| Q4 FY2017 | Dec 31, 2017 | $49.66M | -2.8% |
| Q3 FY2017 | Sep 30, 2017 | $41.86M | -21.0% |
| Q2 FY2017 | Jun 30, 2017 | $39.26M | – |
| Q1 FY2017 | Mar 31, 2017 | $37.65M | – |
| Q4 FY2016 | Dec 31, 2016 | $51.10M | – |
| Q3 FY2016 | Sep 30, 2016 | $52.98M | – |
See a number that looks wrong?